Antiretroviral therapy is continually improving, as new agents and combinations of agents become available that decrease the severe morbidity and mortality associated with HIV infection. As patients’ lifespans increase, it becomes more and more important for clinicians to consider the potential short-term and especially the potential long-term adverse effects of the medications they prescribe.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center reviews the recent postmarketing surveillance that goes beyond the clinical trials to identify previously unrecognized adverse events associated with some of the newer HIV medications.
Assistant Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: February 28, 2019
Expiration date: February 27, 2021